Table 1.

Patient demographics and precedent therapy

Cohort 1: Benign versus neoplastic comparison
Metabolic Pathway	Normal	Nonmuscle invasive		Muscle invasive
		Ta	T1	T2	T3	T4
Number of patients	7	5	3	2	10	4
Mean age	69.7	69.7	67.2	59.3	66.2	66.7
Gendera
Male	5	5	3	2	8	4
Female	2	0	0	0	2	0
Race
Caucasian	5	3	2	2	10	4
African‐American	2	0	0	0	0	0
Other	0	2	1	0	0	0
Prior BCG treatment		1	0	0	2	0
Prior neoadjuvant chemob		0	1	0	2	2

Cohort 2: High‐grade NMIBC versus MIBC comparison
Metabolic pathway	Nonmuscle invasive		Muscle invasive
	High grade Ta	T1	T2	T3	T4
Number of patients	7	10	7	19	5
Mean age	67.6	69.7	74.3	64.3	68.4
Gendera
Male	6	8	7	15	2
Female	1	2	0	4	3
Race
Caucasian	7	8	5	18	5
African‐American	0	2	1	1	0
Other	0	0	1	0	0
Prior BCG treatment	1	3	0	4	0
Prior neoadjuvant chemob	0	0	0	0	0

^aFishers exact test P = 0.3143.

^bFishers exact test P = 0.0030.